Johnson & Johnson Stock

$179.29

0.20%

NYSE, Aug 22, 10:13 pm CET

ISIN

US4781601046

Symbol

JNJ

Reports

Quarter | Annual

Index

Dow Jones, NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Johnson & Johnson Stock price

$179.29

+27.14 17.84% 5Y

NYSE, Closing price Fri, Aug 22 2025

+0.36 0.20%

ISIN

US4781601046

Symbol

JNJ

Reports

Quarter | Annual

Index

Dow Jones, NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$431.8b

Enterprise Value

$463.7b

Net debt

$31.9b

Cash

$18.9b

Shares outstanding

2.4b

Valuation (TTM | estimate)

P/E

19.2 | 16.7

P/S

4.8 | 4.6

EV/Sales

5.1 | 4.9

EV/FCF

25.0

P/B

5.5

Dividends

DPS

$4.91

Yield 1Y | 5Y

2.7% | 2.8%

Growth 1Y | 5Y

4.5% | 5.5%

Payout 1Y | 3Y

84.8% | 53.6%

Increased

25 Years

Financials (TTM | estimate)

Revenue

$90.6b | $94.3b

EBITDA

$30.7b | $35.1b

EBIT

$23.2b | $30.9b

Net Income

$22.7b | $25.8b

Free Cash Flow

$18.5b

Growth (TTM | estimate)

Revenue

4.7% | 6.2%

EBITDA

-4.7% | 13.9%

EBIT

-6.9% | 31.5%

Net Income

-40.4% | 83.7%

Free Cash Flow

-8.6%

Financial Health

Equity Ratio

39.7%

Return on Equity

19.7%

ROCE

16.7%

ROIC

11.8%

Debt/Equity

0.6

EPS

$9.4

FCF per Share

$7.7

Short interest

0.7%

Employees

138k

Rev per Employee

$640.0k

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Johnson & Johnson Stock Analysis

Unlock Scores for Free

29 Analysts have issued a Johnson & Johnson forecast:

13x Buy

45%

16x Hold

55%

More details on Analyst Estimates Including Price Targets

29 Analysts have issued a Johnson & Johnson forecast:

Buy

45%

Hold

55%

Analyst Estimates with Stock Price Targets

Financial data from Johnson & Johnson

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	90,627 90,627	5% 5% 100%
- Direct Costs	29,015 29,015	10% 10% 32%
Gross Profit	61,612 61,612	2% 2% 68%
- Selling and Administrative Expenses	22,932 22,932	4% 4% 25%
- Research and Development Expense	17,034 17,034	14% 14% 19%
EBITDA	30,665 30,665	5% 5% 34%
- Depreciation and Amortization	7,457 7,457	3% 3% 8%
EBIT (Operating Income) EBIT	23,208 23,208	7% 7% 26%
Net Profit	22,661 22,661	40% 40% 25%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Johnson & Johnson Stock News

Positive

Seeking Alpha

●

about 2 hours ago

Best Dividend Kings: August 2025

Dividend Kings underperformed SPY year-to-date but are showing stronger gains in August, with several stocks achieving double-digit returns in 2025. Fifteen Dividend Kings currently appear undervalued with expected long-term annualized returns of at least 10%, based on Dividend Yield Theory analysis. Recent dividend increases have modestly boosted the group's 2025 dividend growth rate, though i...

Neutral

The Motley Fool

●

about 13 hours ago

2 Dividend Stocks Worth Doubling Down on Right Now

Dividend stocks aren't all created equal. Some decrease their payouts, or suspend them altogether, when they face headwinds.

Negative

New York Post

●

2 days ago

Johnson & Johnson to invest $2B in North Carolina plant as Trump's 250% drug tariffs loom

It's a move to boost its domestic production as President Donald Trump threatens to slap devastating tariffs on pharmaceutical imports.

More Johnson & Johnson News

Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Head office	United States
CEO	Joaquin Duato
Employees	138,100
Founded	1887
Website	www.jnj.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now